We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

65 hedge funds and large institutions have $191M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

482% more call options, than puts

Call options by funds: $763K | Put options by funds: $131K

71% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 14

8% less funds holding

Funds holding: 71 → 65 (-6)

32% less capital invested

Capital invested by funds: $279M → $191M (-$88.4M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
65
Holders Change
-6
Holders Change %
-8.45%
% of All Funds
1.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
24
Reduced
14
Closed
15
Calls
$763K
Puts
$131K
Net Calls
+$632K
Net Calls Change
-$2.79M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.59M
2
JGC
J. Goldman & Co
New York
+$849K
3
Charles Schwab
Charles Schwab
California
+$694K
4
PFMU
Privium Fund Management (UK)
United Kingdom
+$416K
5
JP Morgan Chase
JP Morgan Chase
New York
+$355K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$12.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.45M
3
Millennium Management
Millennium Management
New York
-$1.17M
4
IC
Ikarian Capital
Texas
-$861K
5
VOYA Investment Management
VOYA Investment Management
Georgia
-$857K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$68.2M +$237K +27,583 +0.3%
PCM
2
Pentwater Capital Management
Florida
$36.2M – – –
BlackRock
3
BlackRock
New York
$18.5M -$74.5K -8,686 -0.3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11M +$1.59M +184,743 +14%
ACM
5
Aisling Capital Management
New York
$7.61M – – –
Millennium Management
6
Millennium Management
New York
$6.63M -$1.17M -136,267 -13%
PA
7
Perceptive Advisors
New York
$5.74M – – –
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$5.51M -$4.45M -518,944 -41%
State Street
9
State Street
Massachusetts
$3.8M +$64.5K +7,521 +1%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.75M +$1.76K +205 +0.1%
JP Morgan Chase
11
JP Morgan Chase
New York
$2.58M +$355K +41,371 +13%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$2.52M -$165K -19,227 -5%
JGC
13
J. Goldman & Co
New York
$2.2M +$849K +98,890 +49%
RSCM
14
Rock Springs Capital Management
Maryland
$2.11M – – –
SSA
15
Schonfeld Strategic Advisors
New York
$2.11M +$297K +34,576 +14%
ASN
16
Advisory Services Network
Georgia
$1.96M +$98.8K +11,518 +4%
Northern Trust
17
Northern Trust
Illinois
$1.87M +$103K +11,992 +5%
Charles Schwab
18
Charles Schwab
California
$1.52M +$694K +80,870 +63%
N
19
Nuveen
North Carolina
$862K +$71.1K +8,288 +8%
PVI
20
Pura Vida Investments
New York
$834K -$247K -28,777 -20%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$739K +$159K +18,488 +22%
MA
22
MCF Advisors
Kentucky
$482K +$253K +29,431 +80%
Goldman Sachs
23
Goldman Sachs
New York
$416K +$195K +22,718 +66%
PFMU
24
Privium Fund Management (UK)
United Kingdom
$353K +$416K +48,470 New
JIC
25
Johnson Investment Counsel
Ohio
$341K – – –
1
2 3 4

PSTX Hedge Fund Activity: Q3 2021 in Review

65 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2021, worth a combined $191M — down 32% from $279M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PSTX and 9 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 24 added.

The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was Boxer Capital, exiting entirely with an estimated $12.5M sold.

  • 65 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2021, down from 71 in Q2 2021.
  • Funds reported $191M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2021, down 32% quarter-over-quarter.
  • 9 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of -6 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2021 was Vanguard Group, an estimated $1.59M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2021 was Boxer Capital, an estimated $12.5M sold.

Based on aggregated 13F filings for Q3 2021.